OMass Therapeutics 🇬🇧
Series C · $310M
Oxford spinout developing small-molecule drugs for endocrine and immune diseases.
About OMass Therapeutics
OMass Therapeutics is a UK-based company founded in 2016, now around 68 people. It has raised $310M in disclosed funding. FundFinder classes it as Health & Bio.
Founded by Idlir Liko (Founder & Director of Technology; University of Oxford), Jonathan Hopper (Vice President, Platforms and Founder; previously AstraZeneca, AstraZeneca R&D; University of Nottingham).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Want the latest on OMass Therapeutics? Our research agent pulls the current
description, latest round and full investor base from public sources (about a minute).
Series C · $310M · Oct 2026
- Novo Holdings — Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. · cheques £5M – £50M
- Oxford Science Enterprises — Oxford Science Enterprises a university-partnered venture firm, investing in early-stage life science, AI & software, and deep tech. · cheques £5M – £30M